Clinical Evaluation of Homoeopathic Medicines in Benign Prostatic Hyperplasia

2019 ◽  
Vol 32 (02) ◽  
pp. 082-087
Author(s):  
Neeraj Gupta ◽  
Rahul Singh ◽  
R.K. Saxena
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostate Gland ◽  
Prostatic Hyperplasia ◽  
Elderly Men ◽  
Symptomatic Benign Prostatic Hyperplasia ◽  
Daily Lives ◽  
Clinically Significant ◽  
American Urological Association ◽  
Interrupted Flow

Background Symptomatic benign prostatic hyperplasia (BPH) is a common condition in elderly men and has a significant impact on their daily lives. Surgical procedures are currently used for the conventional treatment for BPH; but they have been associated with clinically significant adverse effects in patients. Objectives The main purpose of this article is to evaluate the role of homoeopathic medicines for the treatment of BPH. Materials and Methods Clinically diagnosed 30 subjects of BPH were given homoeopathy treatment and followed up for a period of 1 year. Homoeopathic medicines were prescribed to the subjects according to the principles of homoeopathy. Effects of homoeopathic medicines were analysed periodically by American Urological Association score (AUA score) and ultrasonography. Results Marked amelioration of symptoms and reduction in size of prostate gland in BPH subjects were observed after homoeopathic treatment when analysed by AUA score and ultrasonography. There was marked reduction in various symptoms of BPH like nocturia, straining, incomplete sensation after urination, interrupted flow of urination with dribbling of urine and urgency significantly from 21.60 ± 4.64 units to 12.23 ± 3.68, that is, ∼57% reduction in symptoms of obstruction of bladder problem. The reduction was statistically significant (p = 0.001). However, transabdominal pelvic ultrasonic scan did not show statistically significant results. Conclusion Homoeopathic medicines can prove to be an alternative treatment of BPH.

Diseases of the prostate

2004 ◽  
Vol 14 (2) ◽  
pp. 119-128
Author(s):  
A Cannon ◽  
P Abrams
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostate Gland ◽  
Prostatic Hyperplasia ◽  
Histological Diagnosis ◽  
British Association ◽  
International Continence Society ◽  
Elderly Men ◽  
International Consultation ◽  
Stromal Tissue

Benign enlargement of the prostate gland does not always cause symptoms or obstruction to the flow of urine. Old terminology, for example, ‘prostatism’ can therefore be misleading, and the British Association of Urological Surgeons (BAUS), the International consultation on BPH and the International Continence Society accept the definitions given below:Benign prostatic hyperplasia (BPH) is a histological diagnosis. The first pathological signs appear under the age of 40 years, followed by a rapid increase in prevalence with age; 80% of 80-year-olds have evidence of BPH. The onset of BPH is dependent on the presence of functioning testes and increasing age. It is characterized by a combination of atrophy and proliferation in both glandular and stromal tissue. Although BPH is detectable in most elderly men, it does not always cause enlargement of the prostate, symptoms, or obstruction to the flow of urine.

scholarly journals Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Chao Han ◽  
Lina Zhu ◽  
Xiang Liu ◽  
Shuai Ma ◽  
Yi Liu ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Benign Prostatic Hyperplasia ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Clinical Information ◽  
Clinical History ◽  
Prostatic Hyperplasia ◽  
Imaging Features ◽  
Clinically Significant ◽  
Prostate Diseases

AbstractThe differential diagnosis of abnormalities in the prostate is broad, covering common (acinar adenocarcinoma, benign prostatic hyperplasia, chronic prostatitis, hemorrhage, cysts, calcifications, atrophy and fibrosis) and less common conditions (tumors other than acinar adenocarcinoma, granulomatous prostatitis containing tuberculosis, abscesses and other conditions, and idiopathic disorders such as amyloidosis and exophytic benign prostatic hyperplasia). Recent advances in magnetic resonance imaging (MRI) of the prostate gland and imaging guidelines, such as the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1), have dramatically improved the ability to distinguish common abnormalities, especially the ability to detect clinically significant prostate cancer (csPCa). Overlap can exist in the clinical history and imaging features associated with various common/uncommon prostate abnormalities, and biopsy is often required but is invasive. Prostate abnormalities can be divided into two categories: category 1, diseases for which PI-RADS scores are suitable for use, and category 2, diseases for which PI-RADS scores are unsuitable for use. Radiologists must have an intimate knowledge of other diseases, especially uncommon conditions. Past relevant history, symptoms, age, serum prostate-specific antigen (PSA) levels, MRI manifestations, and the applicability of the PI-RADS assessment should be considered when diagnosing prostate abnormalities.

scholarly journals The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review

2020 ◽  
Vol 7 (3) ◽  
pp. 191-202 ◽  
Author(s):  
Renee E. Vickman ◽  
Omar E. Franco ◽  
Daniel C. Moline ◽  
Donald J. Vander Griend ◽  
Praveen Thumbikat ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Prostate Development
Sign in / Sign up

Export Citation Format

Share Document